Shopping Cart
Remove All
Your shopping cart is currently empty
2-MPPA (GPI-5693) is an orally active, selective, and potent inhibitor of glutamate carboxypeptidase II (GCP II) (IC50: 90 nM) and also a NAALADase inhibitor, used in the study of neurological diseases.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $45 | In Stock | In Stock | |
| 5 mg | $106 | In Stock | In Stock | |
| 10 mg | $172 | In Stock | In Stock | |
| 25 mg | $397 | In Stock | In Stock | |
| 50 mg | $689 | In Stock | In Stock | |
| 100 mg | $1,230 | - | In Stock | |
| 200 mg | $1,670 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $117 | In Stock | In Stock |
| Description | 2-MPPA (GPI-5693) is an orally active, selective, and potent inhibitor of glutamate carboxypeptidase II (GCP II) (IC50: 90 nM) and also a NAALADase inhibitor, used in the study of neurological diseases. |
| Targets&IC50 | GCP II:90 nM |
| In vitro | The application of 2-MPPA (1-20 μM) had no effect on the intrinsic membrane properties of CA3 pyramidal neurons recorded in vitro in whole-cell current clamp or voltage clamp mode. [3] |
| In vivo | 2-MPPA (30 mg/kg intraperitoneally administered) increased jumping behavior in morphine-dependent mice. Opioid-dependent mice treated with 2-MPPA (30 mg/kg, intraperitoneal injection) showed a large number of episodes of tooth trembling. [1] 2-MPPA (10, 30, or 100mg/kg orally) significantly alleviated dizoxepine (0.1mg/kg) -induced PPI deficits in mice in a dose-dependent manner. [2] |
| Synonyms | GPI-5693, GPI5693, 2MPPA |
| Molecular Weight | 206.26 |
| Formula | C8H14O4S |
| Cas No. | 254737-29-6 |
| Smiles | O=C(O)CCC(C(=O)O)CCCS |
| Relative Density. | 1.31g/cm3 |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: 8 mg/mL (38.79 mM), Sonication is recommended. DMSO: 80 mg/mL (387.86 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (16 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
H2O/DMSO
DMSO
| |||||||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.